A substantial population of PCa patients harbors germline or somatic mutations in genes that are involved in the DNA damage repair (DDR) pathway, such as BRCA1/2 and ATM [16], suggesting that these patients may benefit from personalized targeted therapies. The gene discussed is BRCA1; the disease is posterior cortical atrophy.